Healing of a resistant corneal neurotrophic ulcer using a new matrix therapy agent (RGTA)

Abstract

AbstractPurpose To report the case of a patient with a corneal neurotrophic ulcer, resistant to the usual therapies, who has been treated with a new matrix therapy agent (RGTA). CACICOL 20® is a new ophthalmic device, derived from RGTA based matrix therapy (large biopolymers engineered to replace heparan sulfates).Methods We report the case of a monophtalm and deaf‐mute 48 years old woman, who presented with a central neurotrophic corneal ulcer, not responding to the first line therapies, including high dose lubricant eye drops and amniotic membrane graft. To avoid the profound confinement induced by tarsoraphy, a compassional treatment with RGTA CACICOL 20® has been proposed. CACICOL 20® was instilled once every other day for 2 weeks. Biomicroscopic pictures were recorded to follow the cicatrization time course.Results Epithelialization was obtained within 2 weeks with a perfect tolerance. The regimen of instillation was incidently doubled, causing a recurrence, which healed within 2 weeks after the correct regimen was reintroduced.Conclusion This case report is consistent with a strong effect of CACICOL 20® in the treatment of resistant neurotrophic corneal ulcers. The optimal posology and the indications needs to be refined.